Skip to content
Menu

Zura Bio Limited ZURA

Full chart Compare
Set alert

Price alert · ZURA

All alert types
0.93 USD -0.02 (-2.30%)

Regular-session close

0.93 0.00 -0.04%

After hours · Nov 20, 4:00 PM ET

0.9192 Day range 1.00
0.9192 52-week range 7.44
YTD
-82.24%
1 year
-74.65%

5D -0.37 (-26.06%)

11.201.401.60WedThuFriMonTue1.05
Market cap
89.63M
EPS (ttm)
-1.11
Shares out
65.29M
Forward P/E
-3.22
YTD return
-82.24%
1-year return
-74.65%
50-day average
3.61
200-day average
3.76
Enterprise value
-21.57M
Volume
4.76M
Avg volume
4.41M
Open
0.9398
Previous close
0.9524
Day's range
0.9192 – 1.00
52-week range
0.9192 – 7.44
Beta
0.14
Analysts
Strong Buy
Price target
14.29 (+1435.3%)

Key statistics

Price / book
1.02
Free cash flow
-18.87M
Total cash
188.22M
Return on equity
-36.85%
Short % of float
9.54%

Fundamental scorecard

6 of 25 checks passed on ZURA’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ZURA Revenue — quarterly 0
ZURA Net income — quarterly -25.82M
ZURA EPS — quarterly -0.20

Earnings

ZURA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.14-0.26-0.12-85.71%
Aug 13, 2024Jun 1, 2024-0.13-0.17-0.04-30.77%
Aug 13, 2024Jun 1, 2024-0.13———
May 9, 2024Mar 1, 2024-0.23———
May 9, 2024Mar 1, 2024-0.23-0.02+0.21+91.30%
Mar 26, 2024Dec 1, 2023-0.25———

Upgrades / downgrades

ZURA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024Cantor FitzgeraldreitOverweightOverweight
Nov 18, 2024HC Wainwright & Co.reitNeutralNeutral
Nov 11, 2024HC Wainwright & Co.reitNeutralNeutral
Nov 8, 2024Chardan CapitalmainBuyBuy
Nov 4, 2024Leerink Partnersinit—Outperform
Oct 21, 2024HC Wainwright & Co.reitNeutralNeutral

About Zura Bio Limited

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
zurabio.com

News

Your note

Sign in to keep a note on ZURA — it syncs with the Stock Master app.

Insider holders

ZURA insider holders
InsiderRelationLatest transactionDateShares held
CABELL CHRISTOPHER HOfficerStock Award(Grant)May 17, 2023162,060
DAVIS KIMBERLY ANNOfficerStock Award(Grant)May 17, 2023492,381
HOWELL MICHAELOfficerStock Award(Grant)Apr 21, 20240
MUNSHI AMIT DDirectorStock Award(Grant)Apr 21, 2024777,384
NISTALA KIRANOfficerStock Award(Grant)Apr 21, 20243,195
PLOOS VAN AMSTEL ARNOUTDirectorPurchaseMay 16, 2024100,000

Institution ownership

ZURA institution ownership
Holder% heldSharesValueReported
Suvretta Capital Management, LLC7.44%4,860,93911.57MSep 29, 2024
Adar1 Capital Management, LLC 5.77%3,770,6498.97MSep 29, 2024
Deep Track Capital, Lp5.03%3,283,7837.82MSep 29, 2024
Great Point Partners LLC5.00%3,263,6727.77MSep 29, 2024
RA Capital Management, L.P.4.93%3,217,5037.66MSep 29, 2024
Braidwell LP 3.79%2,472,8065.89MSep 29, 2024

Fund ownership

ZURA fund ownership
Holder% heldSharesValueReported
iShares Russell 2000 ETF1.54%1,006,9402.40MOct 30, 2024
Vanguard Extended Market Index Fund0.73%479,1361.14MSep 29, 2024
iShares Russell 2000 Growth ETF0.63%408,101971.28KOct 30, 2024
Fidelity Small Cap Index Fund0.31%203,558484.47KAug 30, 2024
Fidelity Extended Market Index Fund0.31%205,182488.33KOct 30, 2024
Schwab Strategic Tr-Schwab U.S. Small Cap ETF0.20%132,537315.44KAug 30, 2024